Development and evaluation of a combined X-ray transmission and diffraction imaging system for pathology

NIH RePORTER · NIH · R44 · $923,685 · view on reporter.nih.gov ↗

Abstract

ABSTRACT Pathology, which plays a vital role in clinical diagnosis, faces numerous challenges that impact its efficacy. For example, resected specimens often require preparing and analysis of as many as 30-40 slide blocks under a microscope until the disease is confirmed; selection of slices for slide preparation uses subjective methods such as palpation, which depend greatly on the skill of the individual performing the assessment and introduces inconsistency in the clinical process; and for each slide block examined, analysis and annotation requires manual observation of every microscopic region of the tissue. As a result, most pathology evaluations often take 1-3 weeks to analyze samples and reach a conclusion regarding potential cancers. An added challenge is that insurance reimbursements are capped per case regardless of the number of slide blocks processed, with any additional costs being absorbed by the hospital. Consequently, hospitals must balance the trade-off between minimizing the number of slices (for economic viability) and not compromising diagnostic care. These challenges affect not only clinical pathology but also research involving pathology specimens and tissue selection for biobanking. There is a critical need to eliminate subjectivity, reduce pathologists’ workload, and increase throughput in histological analysis. We propose to meet this need by developing a new technology called X-ray diffraction imaging (XRDI), which can scan any number of surgically resected, sliced pathology specimens and automatically indicate the likelihood and location of disease in each slice within minutes. In collaboration with Duke University, we previously built a research prototype XRDI system and demonstrated its utility by scanning and evaluating 300 breast cancer slices with high accuracy and resolution. In this direct-to-phase-II SBIR application, we will now construct a new clinical version of the XRDI scanner that is affordable, reliable, and accurate, and can be directly integrated into the clinical pathology workflow. We will build the scanner, test and evaluate its performance, and demonstrate its utility through field-testing in collaboration with clinical pathology laboratories in the US. This project will provide a first-of-its-kind, commercially feasible XRDI scanner for rapid, non-destructive imaging of pathology specimens with the ability to inform pathologists about the presence and location of cancer within the different tissue slices. The proposed clinical scanner will enable: 1) analysis of the whole slice volume of the specimen rather than a few microns at the surface of a subset of the slices, which is the current standard of care process using microscopy, 2) quantitative identification of disease based on XRD information obtained directly from the tissue, and 3) slice selection based on quantitative, reproducible measurements, thereby eliminating user-related subjectivity. Importantly, it would significantly speed up pathol...

Key facts

NIH application ID
10925188
Project number
5R44EB034645-02
Recipient
QUADRIDOX, INC.
Principal Investigator
Joel Greenberg
Activity code
R44
Funding institute
NIH
Fiscal year
2024
Award amount
$923,685
Award type
5
Project period
2023-09-08 → 2025-08-31